FDA Inspection 1256403 — WuXi Biologics Biosafety Testing (Suzhou) Co., Ltd
The FDA completed an inspection of WuXi Biologics Biosafety Testing (Suzhou) Co., Ltd on Feb 2, 2024 in Suzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 2, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)
Additional Details
Mutual Recognition Agreement (MRA)